Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | KLK7 | P49862 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | CASP1 | P29466 | 4/20 | 0.76 |
| ▸ | CASP7 | P55210 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613313 | 0.99 | KDM4E (0.97) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL20866575 | 0.81 | ALDH1A1 (0.71) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL9613309 | 0.80 | TDP1 (0.67) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL13856682 | 0.78 | PTPN7 (1.00) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL9613292 | 0.78 | FAAH (0.69) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL9613308 | 0.76 | TDP1 (1.00) | KDM4EALDH1A1HPGDHSD17B10CASP1 | |
| SCHEMBL9613366 | 0.76 | KDM4E (0.75) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL8363751 | 0.76 | RAB9A (1.00) | ALDH1A1RAB9AGAAKMT2ASMN1; SMN2 | |
| SCHEMBL17346760 | 0.75 | RAB9A (0.78) | KDM4EALDH1A1HPGDRAB9AGAA | |
| SCHEMBL6037506 | 0.74 | RAB9A (0.96) | ALDH1A1RAB9AKMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353094-B2 | Substituted quinoxalines as kinase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-10-01 | — | — | US | disclosed |
| US-8993758-B2 | Substituted quinoxalines and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012071414-A2 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4E 1991/4885ALDH1A1 4080/4885HPGD 833/4885 |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4E 1991/4885ALDH1A1 4080/4885HPGD 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.